Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2016
Event: Entry into a Material Definitive Agreement (Term Loan) and Termination of a Prior Material Agreement.
Key Financial Metrics and Debt Structure
- Initial Borrowing Capacity: $80.0 million.
- Additional Borrowing Capacity: Up to $45.0 million in two tranches ($25.0 million and $20.0 million), contingent on OMIDRIA revenue or market capitalization milestones.
- Interest Rate: Fixed annual rate of 12.25% (4.0% payable in cash, 8.25% payable in kind/PIK during the interest-only period).
- Term: Six years, maturing September 30, 2022.
- Repayment Structure: Interest-only payments for four years (through December 31, 2020), followed by quarterly principal and interest payments.
- Use of Proceeds: Approximately $75.7 million to repay the Prior Agreement with Oxford Finance LLC and East West Bank; approximately $3.0 million for general corporate purposes and working capital.
- Liquidity Covenant: Required to maintain cash and cash equivalents of $5.0 million.
Material Changes Versus Prior Period
The filing details a refinancing event where Omeros terminated its existing Loan and Security Agreement with Oxford Finance LLC and East West Bank (dated December 30, 2015). This Prior Agreement is being fully repaid using proceeds from the new Term Loan Agreement with CRG Servicing LLC and associated lenders. The new agreement replaces the prior debt structure with a six-year term loan secured by a lien on substantially all of Omeros' assets, including intellectual property.
Guidance, Outlook, Risks, and Contingencies
- Performance Milestones: Additional funding tranches and potential interest rate reductions (to 11.50%) are contingent on achieving minimum net revenue from the ophthalmology product OMIDRIA or specific market capitalization thresholds by June 30, 2017, December 31, 2017, and December 31, 2019.
- Covenants: The agreement includes affirmative and negative covenants restricting indebtedness, liens, mergers, asset dispositions, dividends, and stock repurchases. Annual revenue or market cap thresholds must be met through 2021, or a shortfall payment is required.
- Default Risks: Events of default include non-payment, covenant breaches, material adverse changes, and bankruptcy. A default triggers an additional 4.00% per annum interest rate and potential acceleration of obligations.
- Prepayment: Prepayment is permitted at any time but incurs a fee during the first three years of the term.
Important Facts for Investor Verification
- Verify the current status of OMIDRIA revenue to assess the likelihood of unlocking the additional $45.0 million in funding tranches.
- Confirm the company's ability to maintain the $5.0 million cash and cash equivalents covenant requirement.
- Monitor the company's market capitalization relative to the thresholds required for additional borrowing and interest rate reductions.
- Review the impact of the 12.25% interest rate (with significant PIK component) on future cash flow and debt burden.
- Check for any subsequent filings regarding the satisfaction of the conditions precedent for the initial $80.0 million drawdown.